Metrics as of 10/13/2026, 06:40 PM (Berlin time), refresh in progress.
Viridian Therapeutics Stock
Viridian Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Stephen F. Mahoney
- Employees
- 252
- Market cap
- $2.2 B
- IPO
- 18/06/2014
Viridian Therapeutics, Inc. is a biotechnology firm based in Waltham, US, operating within the Healthcare sector. The company is committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Viridian Therapeutics stock: price history
1D
-2.7%
1W
+2.0%
1M
-15.2%
6M
+28.6%
YTD
-38.8%
1Y
-17.3%
2Y
-20.0%
5Y
+11.5%
10Y
-82.4%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~6% weaker price swings than usual
Ask the agents about Viridian Therapeutics
Analyst assessment of Viridian Therapeutics
PRICE TARGET LOW
US$26.00
CONSENSUS
US$36.43
MEDIAN
US$39.00
PRICE TARGET HIGH
US$43.00
0
STRONG BUY
14
BUY
2
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 22/09/2026
Viridian Therapeutics stock metrics
P/E
-5.39
P/B
3.1
EV/EBITDA
-6.08
RETURN ON EQUITY
-19.2%
NET MARGIN
-44,760.2%
DEBT/EQUITY
0.37
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.8%
FLOAT SHARES
105,160,466
AVG. DAILY VOLUME (30D)
1,974,426
Insider transactions (SEC)
Tousignant Jennifer
Tousignant Jennifer
Tousignant Jennifer
Tripuraneni Radhika
Fairmount Funds Management LLC
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Viridian Therapeutics stock
What does Viridian Therapeutics do?
Viridian Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Stephen F. Mahoney, the company employs around 252 people.
The IPO was on 18/06/2014; the stock trades on NASDAQ under the ticker VRDN.
What do analysts say about Viridian Therapeutics stock?
16 analysts rate the stock, the consensus is Buy (as of 22/09/2026).
The average price target is US$36.43, ranging from US$26.00 to US$43.00, with a median of US$39.00.
This is an external assessment, not a statement by Market Jury.
When does Viridian Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Viridian Therapeutics pay a dividend?
No, Viridian Therapeutics currently does not pay a dividend.
Which stocks are comparable to Viridian Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Viridian Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Viridian Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.